Published in Pediatr Infect Dis J on January 01, 2014
The Clinical Effectiveness of Pneumococcal Conjugate Vaccines. Dtsch Arztebl Int (2016) 1.49
Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type nasopharyngeal carriage. Pediatr Infect Dis J (2014) 1.24
Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on prevention of pneumonia. Pediatr Infect Dis J (2014) 1.23
Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. Pediatr Infect Dis J (2014) 1.22
Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization. Pediatr Infect Dis J (2014) 1.18
Dosing schedules for pneumococcal conjugate vaccine: considerations for policy makers. Pediatr Infect Dis J (2014) 1.01
Reduced middle ear infection with non-typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after transition to 10-valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine. BMC Pediatr (2015) 0.91
Methods for a systematic review of pneumococcal conjugate vaccine dosing schedules. Pediatr Infect Dis J (2014) 0.89
The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity. Pediatr Infect Dis J (2014) 0.88
Serological criteria and carriage measurement for evaluation of new pneumococcal vaccines. Hum Vaccin Immunother (2015) 0.78
Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study. Hum Vaccin Immunother (2015) 0.75
Determinants of effective vaccine coverage in low and middle-income countries: a systematic review and interpretive synthesis. BMC Health Serv Res (2017) 0.75
Mannose-binding lectin-deficient genotypes as a risk factor of pneumococcal meningitis in infants. PLoS One (2017) 0.75
Serotype Distribution and Antimicrobial Resistance of Streptococcus pneumoniae Invasive Isolates Collected at the Italian Hospital of Desio, Lombardy, from 2008 to 2016. Front Public Health (2017) 0.75
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet (2012) 25.96
Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med (1998) 20.81
Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J (2000) 11.94
Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis (2010) 8.37
Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med (2010) 3.25
Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics (1998) 3.13
Extending DerSimonian and Laird's methodology to perform multivariate random effects meta-analyses. Stat Med (2010) 3.07
Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine (2003) 2.87
Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. J Infect Dis (2005) 2.29
Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. Vaccine (2013) 2.18
Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J (1999) 1.84
Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J (2009) 1.80
Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J Infect Dis (2005) 1.61
Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J (2006) 1.57
Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood. Vaccine (1999) 1.43
Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A. Clin Vaccine Immunol (2009) 1.38
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics (2010) 1.36
Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol (2006) 1.30
Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group. Pediatrics (2000) 1.26
Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type nasopharyngeal carriage. Pediatr Infect Dis J (2014) 1.24
Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on prevention of pneumonia. Pediatr Infect Dis J (2014) 1.23
Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom. Pediatr Infect Dis J (2010) 1.23
Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy. Vaccine (2009) 1.23
Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. Pediatr Infect Dis J (2014) 1.22
Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial. Infect Immun (2005) 1.21
Safety and immunogenicity of a nonavalent pneumococcal vaccine conjugated to CRM197 administered simultaneously but in a separate syringe with diphtheria, tetanus and pertussis vaccines in Gambian infants. Pediatr Infect Dis J (2000) 1.13
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol (2010) 1.12
Immunogenicity and reactogenicity of a pneumococcal conjugate vaccine administered combined with a haemophilus influenzae type B conjugate vaccine in United Kingdom infants. Pediatr Infect Dis J (2000) 1.12
Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine. Vaccine (2009) 1.10
Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J (2001) 1.09
Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J Pediatr (1996) 1.08
The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Pediatr Infect Dis J (2009) 1.08
Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants. Vaccine (2005) 1.07
Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J (2009) 1.05
Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate Vaccine. Pediatr Infect Dis J (2005) 1.05
Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants. Vaccine (2006) 1.02
Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in infants. Pediatr Infect Dis J (2004) 1.01
Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr Infect Dis J (2005) 1.00
Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial. JAMA (2005) 0.99
Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine. Pediatr Infect Dis J (2009) 0.99
Pneumococcal conjugate vaccine given shortly after birth stimulates effective antibody concentrations and primes immunological memory for sustained infant protection. Clin Infect Dis (2011) 0.98
Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants. Vaccine (2003) 0.97
Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial. BMC Public Health (2011) 0.97
Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and meta-analysis. Vaccine (2011) 0.96
Response to primary and booster vaccination with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in Korean infants. Pediatr Infect Dis J (2011) 0.96
The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine. Vaccine (2003) 0.95
Safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean children. Hum Vaccin (2011) 0.95
Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine. Clin Infect Dis (2007) 0.92
Serum and salivary anti-capsular antibodies in infants and children vaccinated with octavalent pneumococcal conjugate vaccines, PncD and PncT. Vaccine (2001) 0.90
Methods for a systematic review of pneumococcal conjugate vaccine dosing schedules. Pediatr Infect Dis J (2014) 0.89
Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal conjugate vaccine in infants of Soweto, South Africa. Pediatr Infect Dis J (2002) 0.89
Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine: a randomized controlled trial. Pediatr Infect Dis J (2010) 0.89
The immunogenicity and impact on nasopharyngeal carriage of fewer doses of conjugate pneumococcal vaccine immunization schedule. Vaccine (2011) 0.89
The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity. Pediatr Infect Dis J (2014) 0.88
Safety and immunogenicity of pneumococcal conjugate vaccine in combination with diphtheria, tetanus toxoid, pertussis and Haemophilus influenzae type b conjugate vaccine. Pediatr Infect Dis J (2002) 0.87
Immunogenicity of a heptavalent pneumococcal conjugate vaccine in Apache and Navajo Indian, Alaska native, and non-native American children aged <2 years. Clin Infect Dis (2000) 0.86
Safety and immunogenicity of CRM197-conjugated pneumococcal-meningococcal C combination vaccine (9vPnC-MnCC) whether given in two or three primary doses. Vaccine (2008) 0.86
Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants. Hum Vaccin (2011) 0.83
Comparability of antibody response to a booster dose of 7-valent pneumococcal conjugate vaccine in infants primed with either 2 or 3 doses. Vaccine (2009) 0.83
Immunogenicity and safety of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Taiwan. J Formos Med Assoc (2012) 0.82
Contributions of Native Americans to the global control of infectious diseases. Vaccine (2006) 0.82
Safety and immunogenicity of a 7-valent pneumococcal conjugate vaccine (Prevenar): primary dosing series in healthy Chinese infants. Vaccine (2008) 0.80
Immunology of combining CRM(197) conjugates for Streptococcus pneumoniae, Neisseria meningitis and Haemophilus influenzae in Chilean infants. Vaccine (2009) 0.78
Safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in Taiwanese infants. J Formos Med Assoc (2004) 0.78
Immunization with the heptavalent pneumococcal conjugate vaccine in Bangladeshi infants and effects of zinc supplementation. Vaccine (2007) 0.77
Safety and immunogenicity of two octavalent pneumococcal conjugate vaccines in American Indian infants. Vaccine (2004) 0.76
Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis (2007) 24.91
Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet (2010) 13.86
Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med (2006) 11.49
Global burden of childhood pneumonia and diarrhoea. Lancet (2013) 9.28
Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis (2010) 8.37
Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med (2006) 7.68
U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med (2013) 6.60
Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis (2007) 6.45
Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA (2005) 5.29
Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis (2008) 4.91
Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet (2009) 4.81
Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med (2009) 4.38
Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis (2005) 3.76
Risk of bacterial meningitis in children with cochlear implants. N Engl J Med (2003) 3.75
Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med (2003) 3.54
The Pneumonia Etiology Research for Child Health Project: a 21st century childhood pneumonia etiology study. Clin Infect Dis (2012) 3.40
Standardized interpretation of paediatric chest radiographs for the diagnosis of pneumonia in epidemiological studies. Bull World Health Organ (2005) 3.36
An outbreak of conjunctivitis due to atypical Streptococcus pneumoniae. N Engl J Med (2003) 3.32
Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. J Glob Health (2013) 3.30
Report from a WHO Working Group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae. Pediatr Infect Dis J (2003) 3.29
Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol (2003) 3.27
Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med (2010) 3.25
Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. JAMA (2004) 3.05
Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep (2014) 3.05
Bacterial meningitis in the United States, 1998-2007. N Engl J Med (2011) 2.99
Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2010) 2.95
Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA (2006) 2.93
Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine (2003) 2.87
Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med (2003) 2.87
Revisiting pneumococcal carriage by use of broth enrichment and PCR techniques for enhanced detection of carriage and serotypes. J Clin Microbiol (2010) 2.79
The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines (2012) 2.79
It's time for a change in practice: reducing antibiotic use can alter antibiotic resistance. J Infect Dis (2008) 2.78
Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin Infect Dis (2008) 2.72
Clonal distribution of invasive pneumococcal isolates from children and selected adults in the United States prior to 7-valent conjugate vaccine introduction. J Clin Microbiol (2003) 2.59
Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med (2013) 2.54
Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis (2010) 2.50
Maternal influenza vaccination and effect on influenza virus infection in young infants. Arch Pediatr Adolesc Med (2010) 2.47
Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol (2006) 2.46
Pneumococcal vaccination in developing countries. Lancet (2006) 2.45
PCR-based quantitation and clonal diversity of the current prevalent invasive serogroup 6 pneumococcal serotype, 6C, in the United States in 1999 and 2006 to 2007. J Clin Microbiol (2008) 2.42
Setting research priorities to reduce global mortality from childhood pneumonia by 2015. PLoS Med (2011) 2.36
Seasonal patterns of invasive pneumococcal disease. Emerg Infect Dis (2003) 2.29
Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis (2007) 2.29
Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine. Clin Infect Dis (2008) 2.22
Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob Agents Chemother (2005) 2.14
Lack of association between the nasopharyngeal carriage of Streptococcus pneumoniae and Staphylococcus aureus in HIV-1-infected South African children. J Infect Dis (2006) 2.10
Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine (2007) 2.07
Application of TaqMan low-density arrays for simultaneous detection of multiple respiratory pathogens. J Clin Microbiol (2011) 2.07
Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease. Clin Infect Dis (2010) 2.03
Increased prevalence of pediatric pneumococcal serotypes in elderly adults. Clin Infect Dis (2005) 2.03
Epidemiology of invasive Haemophilus influenzae type A disease among Navajo and White Mountain Apache children, 1988-2003. Clin Infect Dis (2005) 2.01
Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol (2006) 2.00
Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. J Pediatr (2003) 2.00
Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease? PLoS Med (2005) 1.97
Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One (2013) 1.84
Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults. Am J Respir Crit Care Med (2013) 1.84
Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med (2014) 1.84
Improved detection of nasopharyngeal cocolonization by multiple pneumococcal serotypes by use of latex agglutination or molecular serotyping by microarray. J Clin Microbiol (2011) 1.82
Seasonal drivers of pneumococcal disease incidence: impact of bacterial carriage and viral activity. Clin Infect Dis (2013) 1.81
The definition of pneumonia, the assessment of severity, and clinical standardization in the Pneumonia Etiology Research for Child Health study. Clin Infect Dis (2012) 1.78
Shifting genetic structure of invasive serotype 19A pneumococci in the United States. J Infect Dis (2011) 1.75
Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine (2008) 1.74
The burden of acute respiratory infections in crisis-affected populations: a systematic review. Confl Health (2010) 1.72
Changes in invasive Pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med (2006) 1.67
Invasive pneumococcal disease in older adults residing in long-term care facilities and in the community. J Am Geriatr Soc (2003) 1.65
The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis (2005) 1.64
Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis (2007) 1.64
Nasopharyngeal versus oropharyngeal sampling for detection of pneumococcal carriage in adults. J Clin Microbiol (2004) 1.58
Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD). J Leukoc Biol (2003) 1.53
Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother (2004) 1.53
Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis (2006) 1.52
Impact of more than a decade of pneumococcal conjugate vaccine use on carriage and invasive potential in Native American communities. J Infect Dis (2011) 1.51
Association of the pneumococcal pilus with certain capsular serotypes but not with increased virulence. J Clin Microbiol (2007) 1.51
Effect of vaccines on bacterial meningitis worldwide. Lancet (2012) 1.50
Herd immunity and pneumococcal conjugate vaccine: a quantitative model. Vaccine (2007) 1.49
Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population. Clin Infect Dis (2006) 1.47
A longitudinal study of Streptococcus pneumoniae carriage in a cohort of infants and their mothers on the Thailand-Myanmar border. PLoS One (2012) 1.47
Trends in incidence and antimicrobial resistance of early-onset sepsis: population-based surveillance in San Francisco and Atlanta. Pediatrics (2002) 1.47
Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun (2002) 1.46
Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation. J Allergy Clin Immunol (2013) 1.46
Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: a quarter century of experience. J Clin Microbiol (2008) 1.45
Benefits from immunization during the vaccines for children program era - United States, 1994-2013. MMWR Morb Mortal Wkly Rep (2014) 1.44
Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine (2008) 1.43
Strain characteristics of Streptococcus pneumoniae carriage and invasive disease isolates during a cluster-randomized clinical trial of the 7-valent pneumococcal conjugate vaccine. J Infect Dis (2007) 1.43
Laboratory methods for determining pneumonia etiology in children. Clin Infect Dis (2012) 1.38
Emergence of a novel penicillin-nonsusceptible, invasive serotype 35B clone of Streptococcus pneumoniae within the United States. J Infect Dis (2002) 1.38
Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom. J Infect Dis (2002) 1.38
Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. Clin Diagn Lab Immunol (2003) 1.38
Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom. Infect Immun (2003) 1.36